医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Parexel Teams with CLARINESS to Enhance Patient Access and Engagement in China

2019年06月12日 PM10:00
このエントリーをはてなブックマークに追加


 

BOSTON

Parexel, a leader in the development of innovative new therapies to improve the world’s health, today announced a strategic partnership with CLARINESS, a leading global patient recruitment company, to further accelerate clinical trial recruitment and patient engagement in China. The alliance will combine the strength of CLARINESS’ ClinLife® patient portal with Parexel’s extensive local expertise in Asia/Pacific to more efficiently and effectively recruit and retain clinical trial patients in China.

“In China today, digital platforms have become a dominant form of communication, with more than 770 million internet users reported in the country; however, many foreign companies are unable to obtain necessary licenses for compliance to reach these audiences. With our well-established ClinLife platform, Parexel customers will have the opportunity to leverage these effective channels for engagement with patients and clinical trial recruitment,” said Michael Stadler, CLARINESS CEO.

Gadi Saarony, Executive Vice President and Chief Clinical Research Services Officer, Parexel, added, “Parexel’s local expertise and understanding of the Chinese drug development market combined with CLARINESS’ ClinLife digital platform will enable us to reach more patients in China and engage with them through their preferred channels and language while maintaining local compliance. Ultimately this will improve their clinical trial experience while helping to accelerate new therapies to market to the benefit of our customers and patients.”

Celebrating 20 years of presence in Greater China, Parexel has eight offices and over 1,400 employees in the country, as well as more than 8,000 employees in the Asia/Pacific region. CLARINESS has been helping sponsors find patients in Asia since 2005. In addition to providing licensed access to China’s native social media channels, CLARINESS’ services are enhanced through their ability to leverage native speakers to screen and survey patients for potentially underdiagnosed conditions.

About Parexel

Parexel is focused on the development of innovative new therapies to improve the world’s health. We do this through a suite of services that help biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit our website and follow us on LinkedIn and Twitter.

Parexel is a registered trademark of Parexel International Corporation. All other trademarks are the property of their respective owners.

About CLARINESS

CLARINESS develops and implements a wide array of high-end services to pharma corporations and CROs in Europe, North America, Latin America and Asia Pacific including patient recruitment, study feasibility, patient surveys and retention. With 14 years of patient enrollment and engagement experience as well as their inhouse developed ClinLife® technology, CLARINESS has established itself as a leading global patient recruitment expert. ClinLife® is the patient portal for clinical trials, live in 50+ countries with more than 28 languages and has been used by thousands of sites.

www.clariness.com www.clinlife.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005137/en/

CONTACT

Parexel Contacts:
Media:

Wendy Ryan
Tel.:
+1 781-434-5104
Email: Wendy.Ryan@Parexel.com

Kathryn
McMahon Arrigg, PAN Communications
Tel.: +1 617-502-4300
Email: Parexel@pancomm.com

CLARINESS
Contact:

Daniela Zierke
Head of Marketing
Email: daniela.zierke@clariness.com
Tel.:
+49 (0) 40 298 678 07

同じカテゴリーの記事 

  • Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
  • ReNAgade Therapeutics宣布在ASGCT第27届年会上发表演讲
  • ReNAgade TherapeuticsがASGCT第27回年次総会でのプレゼンテーションの内容を発表
  • BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
  • The 2024 Japan Prize Award Ceremony Is Held with Their Majesties the Emperor and Empress of Japan in Attendance